Latest Vaginal ring Stories

Study provides first efficacy data on vaginal rings for HIV prevention Population Council scientists have found that a vaginal ring releasing an anti-HIV drug can prevent the transmission of SHIV in macaques. This study provides the first efficacy data on the delivery of a microbicide from a vaginal ring, and indicates strong potential for the success of such rings in women. Microbicides are compounds that can be applied inside the vagina or rectum to protect against sexually transmitted...

(Ivanhoe Newswire) -- A 15-year Danish historical cohort study was done to see how hormonal contraception can cause thrombotic stroke (blood clotting inside a brain artery) and myocardial infarction (heart attack). In this study, 1,626,158 non-pregnant women from the ages of 15 to 49 years old were observed. During the study 3,311 thrombotic strokes and 1,725 myocardial infarctions occurred. The current use of oral contraceptive that included ethinyl estradiol (bio-active estrogen) at a...

According to court documents, on May 30th, 2012, an Iowa woman, Kristina Marie Isaac, filed a lawsuit in New Jersey District Court (case no. 2:2012cv03240) alleging that her NuvaRing caused her an acute pulmonary embolism. NuvaRing is a popular internal birth control device, a vaginal ring placed near the cervix that was approved by the FDA in 2001. A study published on May 10th 2012 in the British Medical Journal revealed that women who used a vaginal ring had a 6.5 times higher risk for...

According to the study published on May 10th 2012 in the British Medical Journal, non-oral contraceptives, including NuvaRing, have a higher risk of blood clots than combined oral contraceptives (COCs) based on oestrogens and progestins. NuvaRing, approved by the FDA in 2001, is a contraceptive that comes in the form of a vaginal ring using female hormones in an effort to prevent ovulation. Women who used a vaginal ring had a 6.5 times higher risk for developing blood clots compared to...

According to court documents filed on February 28th, 2012, New Jersey state court Judge Brian Martinotti, who is presiding over the NJ Mass Tort for NuvaRing cases (BER-L-3081-09) stated that it is anticipated by the Court that all nine of the selected "bellwether" cases will be ready to be tried on February 4th, 2013. Over in the federal court system, Judge Rodney Sippel has not yet established a firm date for the first trial in the NuvaRing MDL litigation (MDL 1964). NuvaRing...

According to court documents, in a suit filed on Jan. 9 in the Eastern District of Texas, Sherman Division, no. 4:12-cv-00008, a Danton woman, Dawn Kregel, used the NuvaRing for just over a month in 2010. NuvaRing is a contraceptive in vaginal ring form. Kregel accuses the company manufacturing NuvaRing in a $10 million lawsuit stating she was diagnosed with a DVT, allegedly caused by the defendants' products. Now, AttorneyOne.com, a recognized authority on law, can provide helpful,...

New research presented at International Microbicides Conference, May 22-25A flexible ring containing two anti-HIV drugs showed in laboratory tests that it can deliver therapeutic levels of both drugs for up to 30 days, researchers reported today at the International Microbicides Conference (M2010) in Pittsburgh, adding that they consider the ring near ready for testing of its safety in women.Vaginal rings have been used to deliver contraceptives and now this strategy is being applied for...

MORRISTOWN, N.J., March 4 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced an agreement to expand their Women's Health brand product portfolio with the acquisition of the exclusive U.S. rights to Columbia Laboratories, Inc.'s bioadhesive progesterone gel products currently marketed under the trade names CRINONE® and PROCHIEVE® for the indications of infertility and secondary amenorrhea. The two companies will collaborate in the ongoing Phase 3...

MORRISTOWN, N.J. and NEW YORK, March 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced an exclusive licensing agreement to commercialize the Population Council's investigational contraceptive vaginal ring in the United States, Canada, and Mexico. The ring, which contains two hormonal products - ethinyl estradiol and Nestorone®, a novel, synthetic progestin - is currently in Phase 3 clinical development. "This ring, if approved, will provide women with...

NEW YORK (Reuters Health) - Comparison of a contraceptive vaginal ring with an oral contraceptive suggests that the ring does not have a higher risk of causing a blood clot, researchers report in the American Journal of Obstetrics and Gynecology. Lead investigator Dr. Mandana Rad, of the Center for Drug Research, Leiden, the Netherlands, and colleagues note that steroid use in contraception may increase the risk of blood clots, also referred to as venous thromboembolism, through...